Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
PURITAN MEDICAL
Bio-Rad Diabetes Division

Personalized Healthcare Tests Provide Genetic Information on Each Patient

By Labmedica International staff writers
Posted on 19 Feb 2013
Image: genomic biomarkers can help to predict the efficacy and safety of specific treatments in individuals (Photo courtesy of Qiagen).
Image: genomic biomarkers can help to predict the efficacy and safety of specific treatments in individuals (Photo courtesy of Qiagen).
A broad collaboration agreement between two companies will allow the development and commercialization of companion diagnostics. Financial terms of the agreement are not disclosed.

Qiagen (Hilden, Germany) companion diagnostics is collaborating with Lilly medicines (Indianapolis, IN, USA) in an effort to improve outcomes for individual patients.

Companion diagnostics discover a patient’s molecular information in order to guide treatment decisions for specific cancers or other diseases. The agreement builds on Qiagen and Lilly’s past work together. It provides a framework for Lilly and Qiagen to collaborate on future projects, across all of Lilly’s therapeutic areas, aimed at bringing to market Lilly medicines paired with Qiagen diagnostics.

“Tailored therapies are a key component of Lilly’s strategy of providing improved outcomes for individual patients. By working with partners like Qiagen, we are advancing a number of tailored therapeutics in an effort to target the right medicine to the right patient,” said Daniel Skovronsky, MD, PhD, vice president, tailored therapeutics, Lilly, and CEO, Avid Radiopharmaceuticals, a wholly-owned subsidiary of Lilly. “This collaboration with Qiagen extends our capabilities to more quickly and cost-effectively bring innovative new medicines, alongside advanced diagnostics, to patients worldwide who are waiting.”

Qiagen and Lilly have previously collaborated on companion diagnostics designed to run on Qiagen's Rotor-Gene Q system, a component of the QIAsymphony family of automated instruments, which is revolutionizing laboratory workflows. Qiagen's strategy is to develop US Food and Drug Administration (FDA; Silver Spring, MD, USA) approved diagnostics in the United States for use on this platform.

Related Links:
Qiagen
Lilly medicines
US Food and Drug Administration



ADVANCED INSTRUMENTS
DIASYS DIAGNOSTIC SYSTEMS
KARL HECHT GMBH & CO KG
WATERS CORPORATION

Channels

Genetic Tests

view channel

Overexpression of X Chromosome Genes Is Biomarker for Female Mental Disorders

A recent paper suggested that elevated expression of the genes XIST (X-inactive specific transcript) and KDM5C (lysine-specific demethylase 5C) could be used as a biological marker for diagnosis of major affective disorders in a significantly large subset of female patients from the general population. Xist is an RNA... Read more

Immunology

view channel

Powerful Innovations in Diagnostics Unveiled at EuroMedLab 2015

New systems presented by Roche include a new standard for immunology testing, an integrated platform for hematology diagnostics, and a high-throughput analyzer to perform HbA1c tests for blood glucose management. Also, evidence was presented for a high-sensitivity cardiac troponin test to provide earlier and more accurate... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.